Genome editing and food safety: bridging the validation gap

Abstract

Genome editing is increasingly positioned as a tool for improving food safety and nutritional quality, yet its real-world impact depends on outcomes that extend far beyond molecular precision. This review synthesizes evidence on how genome edits translate through phenotypes, food matrices, processing, microbial ecology, and dietary exposure, revealing a persistent validation gap between early-stage technical metrics and food-safety–relevant endpoints. We argue for an exposure-anchored, multi-layered validation framework incorporating omics, post-harvest behavior, and post-market monitoring. Closing this gap is essential for aligning genome editing innovations with measurable improvements in food system safety and consumer protection.

The validation gap in genome-edited foods

Genome editing technologies, particularly CRISPR–Cas systems, are frequently discussed as tools capable of improving crop resilience, nutritional quality, and potentially aspects of food safety. However, the evaluation metrics used to assess genome editing success are primarily molecular and technical in nature, whereas food safety assessment relies on exposure-relevant evidence related to toxicology, allergenicity, microbial behavior, and consumption patterns. This misalignment creates what we describe as a “validation gap,” in which the evidence generated during genome editing development does not always correspond to the evidence required for food-safety-relevant risk assessment.

Genome editing technologies are widely characterized by their technical precision and efficiency in introducing targeted genetic changes. This perception has contributed to a growing narrative in which genome editing is sometimes implicitly equated with improved food safety and quality, although empirical studies and consumer perception research indicate that such assumptions remain contested and context dependent^1,2. At the technical level, genome editing success is typically defined by metrics such as on-target modification efficiency, reduced off-target activity, and genetic stability across generations. These parameters are essential for confirming that an intended genetic change has occurred, yet they represent only an early stage in the food safety evaluation pathway. Food safety, by contrast, is inherently outcome-oriented, encompassing compositional integrity, allergenicity, toxicological relevance, microbial behavior, and dietary exposure under real-world conditions. Conflating molecular precision with safety therefore risks overlooking critical downstream determinants of risk^1,3–6.

This validation gap is not unique to genome editing, but its implications are amplified by the speed at which edited traits can be developed and deployed. Unlike earlier transgenic approaches, genome-edited products may enter the food system with fewer regulatory triggers in certain jurisdictions, particularly where product-based regulatory frameworks apply. Regulatory approaches toward genome-edited crops vary substantially across jurisdictions. Countries such as the United States, Japan, and Argentina primarily follow product-based regulatory frameworks, where genome-edited crops lacking foreign DNA may be exempt from strict GMO regulation. In contrast, the European Union currently regulates many genome-edited organisms under existing GMO legislation, although policy discussions on revised frameworks are ongoing. These differences influence the evidentiary requirements for safety assessment and may contribute to uneven validation expectations across global food systems^6,7. As a result, the evidentiary burden may shift away from comprehensive safety characterization toward assumptions of equivalence based on editing technique alone^8–11. While these assumptions may support rapid technological deployment, the available food safety literature indicates that molecular editing outcomes alone provide limited information about downstream exposure and consumer risk.

A central contributor to the validation gap is the limited predictability of phenotypic outcomes following targeted genetic changes. Even when edits are precisely characterized at the DNA level, phenotypic expression can vary depending on genetic background, environmental conditions, and agronomic practices. These factors may influence plant metabolism, compositional traits, and interactions with microbial communities, many of which remain outside the scope of routine molecular validation pipelines^12–16.

One commonly cited example illustrating this disconnect involves disease resistance traits. Genome editing is frequently promoted to reduce foodborne risk by limiting pathogen pressure at the primary production stage. While disease resistance may contribute indirectly to food safety, its effect is conditional and context dependent. Post-harvest handling, processing, storage, and distribution exert a dominant influence on microbial contamination and persistence, often overwhelming upstream genetic interventions. Treating disease resistance as a proxy for food safety, therefore, represents a conceptual oversimplification that reinforces, rather than resolves, the validation gap^17–21. The persistence of this gap is also reflected in regulatory practice. Risk assessment frameworks have historically relied on comparative approaches, emphasizing substantial equivalence and targeted testing. Although these approaches provide a pragmatic basis for decision-making, they are not designed to systematically interrogate complex, multilevel pathways linking genome edits to dietary exposure. Consequently, regulators face increasing pressure to interpret advanced datasets, particularly omics outputs, without clear guidance on how such data should inform safety conclusions^22–27.

Recent policy and governance analyses have highlighted that unresolved validation gaps undermine public trust and complicate international regulatory alignment. Divergent interpretations of what constitutes sufficient evidence for safety contribute to inconsistent oversight and reinforce perceptions of regulatory arbitrariness. From a food systems perspective, the challenge is therefore not merely technical but structural: aligning validation practices with the multidimensional nature of food safety risk^7,28–34.

This Review adopts the concept of a validation gap as an organizing framework to critically examine how genome editing is currently assessed in relation to food safety and quality. Rather than evaluating genome editing as a standalone technology, we focus on the evidentiary disconnects that arise as edited traits move from the laboratory to the food chain. By situating genome editing within a broader food safety context, this approach provides a foundation for identifying where current validation practices fall short and how they may be recalibrated to support credible, exposure-relevant risk assessment.

From genome editing to dietary exposure

From this section to the fourth section, the manuscript examines the validation gap from complementary perspectives. This section traces how genome editing outcomes propagate through the food system toward dietary exposure. Section “Post-editing validation: What is currently missing?” examines limitations in current validation practices. Section “Omics data and regulatory blind spots” discusses how emerging omics tools highlight additional evidence gaps within regulatory assessment frameworks.

Genome editing outcomes are most often evaluated at the level of genetic modification itself. Editing efficiency, target specificity, and genetic stability across generations are routinely used as indicators of success. While these metrics are essential for confirming that an intended modification has occurred, they represent only the initial step in a pathway that ultimately determines food safety at the level of human exposure^8–10.

Food safety assessment for genetically modified crops has historically been shaped by international frameworks developed by FAO/WHO Codex Alimentarius, the European Food Safety Authority (EFSA), and regulatory agencies such as the United States Food and Drug Administration and USDA. These frameworks emphasize comparative risk assessment, compositional analysis, and targeted testing of potential hazards. While these approaches were originally developed for transgenic crops, many of their principles continue to inform the evaluation of genome-edited products, although implementation varies across jurisdictions^27,33.

Food safety does not emerge at the point of DNA alteration. It emerges when food is consumed. Between genome editing and dietary exposure lies a multilevel trajectory that includes phenotypic expression, food matrix integration, post-harvest handling, and consumption patterns. Each of these stages can modify, amplify, or attenuate the relevance of an initial genetic change. Validation strategies that focus narrowly on early-stage molecular outcomes, therefore, risk overlooking the stages at which safety-relevant effects are most likely to manifest¹¹.

The first transition in this pathway occurs at the level of phenotype. Even when genome edits are precisely characterized at the molecular level, genotype–phenotype relationships remain context dependent. Environmental variation, agronomic conditions, and genetic background can influence how edited traits are expressed, highlighting the importance of monitoring phenotypic and compositional outcomes beyond the molecular stage^12–14. These effects are particularly relevant for traits that indirectly affect composition rather than producing discrete, easily measurable changes.

Phenotypic change, however, does not directly equate to food safety relevance. Edited traits enter the food system through specific food matrices that shape chemical composition, nutrient bioavailability, and interactions with microbial communities. Food matrices actively influence how endogenous compounds are processed, transformed, and absorbed. Modest changes in protein expression, carbohydrate structure, or secondary metabolite profiles may have limited significance at the crop level but acquire relevance once incorporated into processed foods or composite diets^15,16.

Post-harvest handling and processing introduce a further layer of complexity. Thermal treatment, fermentation, storage, and packaging can alter chemical profiles independently of the original genetic modification. In some cases, processing may reduce compositional differences; in others, it may generate new exposure-relevant compounds or concentrate existing ones. Validation pipelines that end prior to post-harvest evaluation, therefore, provide an incomplete representation of the food safety landscape^19–21.

Dietary exposure represents the final and decisive stage of this pathway. Exposure is shaped not only by compositional attributes but also by consumption frequency, portion size, and population heterogeneity. Widely consumed staple foods may generate meaningful exposure even when compositional changes are subtle, whereas substantial molecular changes may be toxicologically irrelevant if intake remains low. Without explicit exposure considerations, validation remains disconnected from practical risk assessment^17,18.

Figure 1 conceptualizes the multilevel pathway through which genome editing outcomes translate into potential food safety implications. The framework maps successive stages—from the initial genetic modification to phenotype expression, food matrix integration, post-harvest processing, microbial interaction, and ultimately dietary exposure. By explicitly representing these stages, the figure highlights where validation evidence is currently concentrated and where critical safety-relevant information may remain underexplored. Each stage in the pathway represents a point at which evidence relevant to food safety can emerge or be obscured. By explicitly mapping these stages, the framework highlights where current validation practices disproportionately concentrate evidence generation.

Fig. 1.

From genome editing to food safety outcomes: a multilevel validation framework (Created using Canva).

Disease resistance traits are frequently cited as examples of genome editing delivering direct food safety benefits along this pathway. While reduced disease burden may lower contamination pressure under certain conditions, this effect is conditional and often secondary to post-harvest controls. Sanitation practices, processing environments, and supply chain dynamics exert a dominant influence on microbial contamination and persistence, limiting the extent to which disease resistance alone can be interpreted as a food safety intervention^25–27.

From a food systems perspective, the pathway from genome editing to dietary exposure is therefore discontinuous rather than linear. Validation approaches that privilege early-stage success metrics risk misrepresenting downstream risk and reinforcing the validation gap identified in this Review. Addressing this gap requires reorienting assessment frameworks toward later stages of the pathway, where exposure and public health relevance are ultimately determined^22–24.

Post-editing validation: What is currently missing?

Current validation pipelines for genome-edited crops remain heavily front-loaded: most of the effort is invested in demonstrating edit efficiency, on-target accuracy, genetic stability across generations, and basic compositional comparability to a conventional comparator. These metrics are necessary, but they represent only a narrow subset of the endpoints that actually matter for food safety and nutritional quality^27,35,36. As a result, many genome-editing case studies declare “safety” on the basis of limited molecular and compositional evidence, without systematically interrogating downstream toxicological, allergenic, microbial, or exposure-relevant consequences.

One of the clearest gaps concerns toxicological assessment for edits affecting metabolic or regulatory genes. Early food safety frameworks developed for genetically modified crops were largely designed around first-generation transgenic traits, such as insect resistance and herbicide tolerance, where the toxicological focus was often limited to one or a few newly expressed proteins and their known functional properties^27,36,37. Within that context, comparative compositional analysis and targeted toxicological testing provided a pragmatic basis for safety evaluation^27,35,36. By contrast, genome editing is increasingly being used to modify endogenous metabolic pathways, stress responses, and developmental processes, where pleiotropic and context-dependent effects are more plausible and may not be adequately captured by these earlier assumptions^24,38–40. Yet toxicological evaluation still often relies on narrow 90-day rodent studies or limited in vitro endpoints that are poorly aligned with the broader range of plausible outcomes associated with edited metabolic pathways³⁸. For many edited traits, there is still no systematic attempt to connect the molecular alteration to adverse-outcome pathways, exposure-relevant toxicological scenarios, or margins of safety grounded in realistic dietary intake^18,19,24.

Another underdeveloped dimension is the integration of off-target and on-target structural changes into food-relevant risk scenarios. Genome-wide studies have documented that CRISPR/Cas-based systems can generate large deletions, complex rearrangements, and low-frequency off-target mutations, which are sometimes missed by targeted assays^12,14,37,41. In practice, however, off-target analysis in agricultural applications is often limited to a small number of predicted sites, and the interpretation is usually framed in purely genomic terms (“no biologically relevant events detected”), without connecting potential structural changes to compositional shifts, altered metabolite profiles, or food processing behavior. This creates a conceptual separation between genome integrity data and the endpoints that ultimately determine consumer risk.

Beyond chemical composition, microbial ecology and food matrix effects remain largely absent from post-editing validation. Multiple studies have shown that pre-harvest practices and post-harvest handling dominate microbial risk in fresh and minimally processed foods, with contamination and growth often occurring long after any genetic trait has exerted its agronomic function^42–45. At the same time, emerging work on food microbiomes and microbiome-based indicators shows that community composition can act as a sensitive hazard signal in supply chains^46–48. Yet validation studies for genome-edited crops rarely include systematic assessment of how the edited plant interacts with epiphytic, fermentative, or spoilage microbiota, or whether the trait influences susceptibility to microbial contamination during storage, processing, or distribution.

Post-harvest behavior further complicates the validation landscape. Shelf-life, physiological stress responses, and susceptibility to spoilage or mycotoxin formation are all strongly influenced by post-harvest technologies such as temperature management, controlled atmosphere storage, edible coatings, and active packaging^{42–44,49,50}. Genome-edited traits that modify plant stress physiology, cuticle properties, or metabolite profiles could interact with these technologies in ways that alter microbial growth, toxin formation, or nutrient stability, yet such interactions are almost never explored. The result is a validation picture that ends at harvest, even though most food safety incidents are linked to failures occurring post-harvest.

Allergenicity assessment illustrates both progress and inertia. Regulatory guidance has converged on a weight-of-evidence, case-by-case framework that combines bioinformatics, in vitro digestibility, and targeted serology for newly expressed proteins and relevant endogenous allergens²⁵. This framework has been effective at preventing clear-cut cases such as transfer of major allergenic proteins⁵¹. However, for genome-edited crops that modulate endogenous pathways rather than introducing foreign proteins, the current toolkit is less obviously fit-for-purpose. There is limited guidance on how to handle small but systematic shifts in allergen content, cross-reactive epitopes, or matrix-dependent changes in protein digestibility, especially in multi-ingredient foods⁵².

Post-market monitoring (PMM) remains the final missing layer in most genome-editing case studies. Experience with GM crops such as MON810 shows that structured PMM programs, combining farmer questionnaires, environmental monitoring, and literature surveillance, can provide long-term evidence on real-world performance and unintended effects^53,54. Current EFSA guidance also emphasizes the role of PMM as a backstop to detect unanticipated effects that escaped pre-market risk assessment²⁷. In practice, however, most genome-editing applications either omit PMM entirely or rely on minimal, non-hypothesis-driven monitoring that is unlikely to detect subtle but cumulative changes in exposure or safety. This leaves a structural blind spot precisely where the complexity of food systems is highest.

Taken together, these gaps mean that post-editing validation is still largely organized around early-stage, laboratory-convenient metrics rather than the endpoints that regulators and public health authorities actually need. Figure 2 contrasts the dominant validation metrics reported in genome-editing studies with the evidence categories required for food-safety-relevant assessment, illustrating the structural misalignment that constitutes the validation gap. Additionally, Fig. 2 illustrates that commonly reported genome editing metrics predominantly correspond to early technical validation stages, whereas food safety assessment requires evidence linked to exposure and real-world food system behavior. Table 1 operationalizes this comparison by mapping concrete validation practices against their criticality for food safety and their current regulatory relevance. As the table shows, many of the routinely performed checks are only weakly informative for consumer risk, whereas several high-impact domains, microbial ecology, long-term exposure, and real-world performance, remain rarely addressed.

Fig. 2.

Disconnect between genome editing success metrics and food safety endpoints (Created using Canva).

Table 1.

Current validation practices vs. required food safety assessments for genome-edited foods^24,25,27,39

Validation Aspect	Commonly performed	Rarely performed	Critical for food safety	Regulatory relevance
Genetic stability	✓ Routine assessment of edit inheritance and target-site integrity across generations	✕ Long-term stability under environmental stress conditions	◐ Indirect – relevant for trait consistency rather than direct hazard reduction	◐ Considered as supporting evidence but not sufficient alone
Off-target effects	✓ Targeted off-target screening using prediction tools and limited sequencing	✕ Genome-wide, untargeted detection across multiple tissues and generations	◐ Potential relevance if unintended changes affect safety-related pathways	◐ Increasingly scrutinized, but interpretation remains case-specific
Metabolomics	✕ Rarely included beyond targeted compositional analysis	✓ Untargeted metabolomic profiling linked to exposure thresholds	✓ Directly relevant for detecting unintended biochemical changes	✓ Highly relevant but not yet standardized in regulatory practice
Allergenicity	✓ In silico sequence comparison and known allergen screening	✕ Functional or in vivo allergenicity testing	✓ Critical, particularly for edits affecting regulatory or metabolic genes	✓ Central to regulatory food safety assessment
Microbial ecology	✕ Typically excluded from validation studies	✓ Assessment of plant–microbe and food matrix interactions	✓ Relevant for spoilage, pathogen persistence, and toxin production	◐ Emerging relevance, rarely addressed explicitly
Post-harvest behavior	✕ Rarely assessed beyond yield and quality traits	✓ Evaluation under storage, processing, and distribution conditions	✓ Critical, as many foodborne risks arise post-harvest	✓ Increasing relevance for comprehensive safety evaluations

Symbols indicate the relative level of current implementation or relevance: ✓ widely applied; ◐ partially implemented or context-dependent; ✕ rarely applied.

In this sense, the “validation gap” is not simply an absence of data, but a systematic misalignment between what is measured and what is needed for robust food safety conclusions. Closing that gap requires re-orienting post-editing validation around downstream exposure and system-level behavior, rather than treating molecular confirmation as an endpoint.

Integrating omics data into food safety risk assessment

The rapid expansion of omics technologies—genomics, transcriptomics, proteomics, metabolomics—has been widely promoted as a way to modernize safety evaluation for both GM and genome-edited crops. Early work demonstrated that high-throughput profiling can sensitively capture changes in gene expression and metabolite levels caused by genetic modification, environmental conditions, or agronomic practices^20,21. In principle, these tools could help identify unexpected compositional changes, detect pathway-level perturbations, and support a more mechanistic understanding of potential hazards.

However, experience over the past decade indicates that the contribution of omics to regulatory food safety assessment remains modest and uneven. Major reviews of omics-based GM crop assessments conclude that environmental and genetic background effects typically explain more variance in omics profiles than the modification itself, and that observed differences are rarely of toxicological significance^35,38. This has led several authors and expert panels to argue that, while omics can be scientifically informative, its added value relative to targeted compositional analysis is context-dependent and often difficult to translate into clear weight-of-evidence judgments³⁸. A central limitation is the lack of standardized, decision-oriented interpretation frameworks. Current regulatory guidance still anchors safety assessment in the concept of comparative or “substantial” equivalence, supported by targeted analysis of predefined nutrients, anti-nutrients, and toxicants²⁷. Omics datasets, by contrast, generate hundreds or thousands of variables, making it non-trivial to distinguish biologically trivial variation from changes warranting follow-up. Without agreed thresholds for concern, clear criteria for selecting follow-up endpoints, or harmonized statistical workflows, omics results risk becoming either over-interpreted or ignored.

Metabolomics, which is arguably the omics modality closest to traditional compositional analysis, illustrates both the promise and the problem. Studies in maize and other crops show that metabolomic profiles are highly sensitive to environment, genotype, and agronomic practices, with GM or edited traits usually falling within the broader range of conventional variation^55,56. This supports the notion that many edits will not generate qualitatively new metabolites or hazardous shifts in known compounds. At the same time, the very breadth of metabolomic coverage makes it difficult to define which subset of signals should trigger toxicological or nutritional concern, especially when changes are modest and distributed across pathways.

From a food safety perspective, the more fundamental issue is that omics studies rarely extend beyond raw plant tissues under controlled growth conditions. By design, they typically do not incorporate processing (thermal treatments, fermentation, drying), storage, or interactions with microbial communities—steps that can dramatically reshape exposure profiles^42,43,49. As a result, rich molecular data are generated at a stage of the chain where many hazards have not yet emerged and where the relevance for final consumer exposure is indirect.

Regulatory bodies have started to acknowledge both the potential and the limitations of omics. EFSA, for example, has emphasized that untargeted omics may be useful as a hypothesis-generation tool or as supplementary evidence, but has stopped short of making it a core requirement for GM or genome-edited crop assessment until interpretive and standardization challenges are resolved^27,38. Similar cautious positions are reflected in OECD and national guidance documents, which recognize omics as scientifically valuable but not yet operationalized within routine regulatory workflows.

Omics technologies have expanded our capacity to observe molecular consequences of genome editing, but they have not yet been systematically integrated into food safety risk assessment in a way that closes the validation gap. Their greatest unrealized potential lies in being embedded within multi-level validation frameworks, linking molecular signals to phenotypic behavior, processing outcomes, microbiome interactions, and exposure metrics, rather than being treated as large but isolated datasets. Figure 1 and Table 1 in this Review highlight how omics could be repositioned from an optional add-on toward a more strategically deployed component of food-safety–centered validation.

Omics data and regulatory blind spots

Omics technologies, including metabolomics, transcriptomics, and proteomics, hold promise for revealing unintended molecular changes that traditional targeted analyses might miss. When applied to genome-edited crops, omics can detect alterations in pathways affected by editing, environmental interaction, or genetic background, providing a broad molecular snapshot beyond preselected endpoints^2,57. However, their integration into formal food safety assessments remains limited due to interpretative and standardization challenges^9,24.

A central challenge lies in moving from observation to inference. Untargeted omics datasets often contain thousands of features, many of which reflect natural biological variation or environmental influences rather than treatment effects. In the absence of established benchmarks or effect thresholds, distinguishing meaningful signals from background variation becomes ambiguous. Regulatory agencies have noted that while omics platforms can support hypothesis generation, they do not yet offer a clear decision framework for risk characterization³⁹.

Comparative frameworks grounded in substantial equivalence further limit the utility of omics. The core regulatory paradigm in food safety holds that an edited or modified product should be compared with a conventional counterpart to identify relevant differences⁵⁸. Yet omics amplifies both targeted and incidental variation, making it difficult to determine which differences are truly safety relevant. Analogous experience from the broader GM crop risk assessment literature shows that most omics differences fall within the natural range of variation and do not indicate toxicologically relevant effects³⁹.

Even when differences are statistically significant, their biological relevance is often unclear. Without mechanistic anchors or linkages to exposure or adverse outcome pathways, omics outputs risk remaining descriptive rather than interpretive²⁴. Regulators and expert panels have emphasized the need for clear criteria on how omics would influence safety decisions before they can be incorporated into routine assessment protocols. Another practical barrier is methodological consistency. Omics results can vary substantially with laboratory protocols, analytical platforms, and data processing approaches. Until harmonized standards and quality controls are established, inter-laboratory comparability remains elusive, further complicating regulatory uptake³⁹.

Despite these limitations, omics hold conceptual value within a multi-layered validation framework. When combined with targeted compositional analysis, phenotypic characterization, and exposure assessment, omics can help prioritize follow-up testing and identify potential pathways of concern. Rather than substituting hypothesis-driven experiments, integrated strategies that use omics as a complementary layer can help bridge the validation gap between molecular edits and safety outcomes under real-world conditions.

Toward a food-safety–centered validation framework

A food-safety–centered validation framework shifts the focus from early technical indicators to exposure relevance and real-world endpoints. Historically, evaluation methods for genetically modified organisms, including genome-edited crops, were built around concepts such as substantial equivalence and targeted compositional comparators⁵⁸. Yet this paradigm was established when modification was largely constrained to introducing discrete transgenes; genome editing now enables subtler modifications to endogenous genes and regulatory regions, increasing the complexity of downstream effects^39,40.

Under a food-safety framework, the first requirement remains confirmation of the intended edit and assessment of unintended on-target or off-target modifications. However, these must be interpreted considering functional consequences, not just presence or absence of change. For example, an edit that modifies stress response pathways may alter metabolites involved in plant defense or secondary metabolism, which in turn could influence microbial ecology during processing or consumption stages²⁴.

Exposure must anchor validation priorities. Changes that plausibly affect dietary exposure, such as shifts in nutrient levels, allergen content, or bioactive compounds, should be systematically investigated. This includes rigorous compositional analyses that align with known metabolic pathways relevant to human health. Harmonization of compositional data with known safety benchmarks enhances interpretability⁵⁸. Another pillar of this framework is the explicit consideration of post-harvest behavior. Traits that might influence physiological status at harvest can interact with storage conditions, processing technologies, or microbial populations, altering exposure profiles in ways that cannot be predicted from harvest-stage data alone. Post-harvest evaluations, including shelf-life assessment and microbial growth dynamics under relevant conditions, provide complementary evidence that bridges early validation and real-world outcomes^{2,9,24,39,40,57–60}.

Post-market monitoring (PMM) completes the lifecycle perspective. Monitoring real-world performance and safety outcomes aftermarket release allows detection of unanticipated effects and supports iterative risk refinement. Although much of the existing PMM experience comes from environmental monitoring for GM crops, the principles are transferable and have been highlighted by regulatory bodies as useful backstops for emerging technologies⁶⁰.

International governance can facilitate harmonized adoption of these principles. Divergent regulatory models, ranging from product-based to process-based approaches, create inconsistencies in evidence expectations that complicate both innovation and comparative risk assessment. Broad alignment on core validation principles, even in the absence of uniform regulation, can improve clarity for developers and regulators alike. Collaborative platforms such as Codex Alimentarius and FAO offer venues for codifying shared expectations for exposure-centered validation⁵⁸. By redefining validation to embrace exposure relevance, post-harvest behavior, and post-market observation, this framework mitigates the risk of narrow, early-stage validation that fails to translate into real safety outcomes. It aligns scientific evidence generation with public health priorities and contextualizes genome editing within the broader dynamics of food systems.

For regulatory authorities, a food-safety–centered validation framework implies three practical priorities: aligning molecular validation with downstream exposure-relevant endpoints, integrating omics-based hypothesis generation with targeted follow-up testing, and strengthening post-market monitoring systems capable of detecting unexpected effects in complex food systems.

Conclusion

Genome editing continues to evolve as a powerful tool for crop improvement, nutritional enhancement, and resilience building. However, realizing its potential for food safety requires expanding how validation is conceptualized. The traditional emphasis on molecular precision and early compositional metrics must give way to frameworks that prioritize exposure, context, and lifecycle perspectives. Future research should integrate targeted follow-up endpoints with high-resolution molecular insights, ensuring that omics data informs rather than obscures risk characterization. Regulatory science must concurrently adapt by clarifying how diverse evidence streams are weighed and interpreted within decision-making processes.

International cooperation will be key for harmonizing validation expectations without imposing uniform regulatory regimes. Shared principles can support mutual recognition of evidence packages and facilitate innovation while preserving public confidence in safety assessments. Ultimately, genome editing’s contribution to safer, more nutritious food systems depends not only on technical advances but on the alignment of validation practices with real-world risk pathways. Bridging the validation gap is both a scientific and a governance challenge, one that demands integrated strategies, pragmatic benchmarks, and a clear focus on exposure-driven outcomes.

Looking forward, advances in high-resolution metabolomics, food-microbiome profiling, and probabilistic exposure modeling offer opportunities to operationalize a more predictive validation framework. Integrating these tools with adaptive regulatory pathways could transform genome editing from a molecular innovation into a reliably food-safe system innovation.

Author contributions

Y.E. has made the conceptualization, investigation, drafting, writing original and final approval of the manuscript. P.S.K. has contributed for the methodology of the investigation, has made the drafting, final approval of the manuscript.

Data availability

No datasets were generated or analyzed during the current study.

Competing interests

The authors declare no competing interests.